Please login to the form below
Swedish Orphan Biovitrum
This page shows the latest Swedish Orphan Biovitrum news and features for those working in and with pharma, biotech and healthcare.
Sobi to acquire CTI BioPharma for approximately $1.7bn
The deal marks a notable expansion to the Swedish drugmaker's rare haematology pipeline. ... Swedish Orphan Biovitrum (Sobi) has said it will acquire CTI BioPharma for approximately $1.7bn, marking a notable expansion to the Swedish drugmaker's rare
Latest news
-
Sanofi and Sobi’s efanesoctocog alfa granted FDA priority review for haemophilia A
Sanofi and Swedish Orphan Biovitrum's (Sobi) Biologics Licence Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of haemophilia A has been accepted by the US Food and Drug Administration ... The European Commission (EC) also granted
-
Sanofi and Sobi announce positive phase 3 trial results for severe haemophilia A
Sanofi and Swedish Orphan Biovitrum (Sobi) have announced positive results from a phase 3 trial, showing once-weekly efanesoctocog alfa provided ‘clinically meaningful’ bleed protection for patients with severe haemophilia A. ... The European
-
Sobi set to spend up to $915m to acquire Dova Pharmaceuticals
Hopes to boost haematology franchise with lead drug Doptelet. Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval ... It was cleared by the FDA for primary
-
Sobi shows strong growth despite haemophilia competition
Looking to M&A for continued growth. Rare disease specialist Swedish Orphan Biovitrum (Sobi) has posted strong growth for the first quarter of the year, led by its haemophilia franchise.
-
US, EU regulators back rapid reviews of AZ’s RSV med
With MEDI8897, AZ and its partners for the drug – Sanofi and Swedish Orphan Biovitrum (Sobi) – have the opportunity to open up the RSV prevention market beyond high-risk patients, as its
More from news
Approximately 5 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
A rare opportunity
Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions. ... The UK, in common with many developed markets, has large numbers of products that, while they do have a licence and are currently available, are rarely
-
Deal Watch table for July 2013
49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum. Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Sobi poaches Pfizer’s Fredrick Wetterlundh
Swedish Orphan Biovitrum (Sobi) has appointed Fredrik Wetterlundh as head of human resources and will simultaneously be part of Sobi’s extended leadership team.
-
Mereo BioPharma appoints head of patient access and commercial planning
With extensive experience in the rare and orphan disease areas, she will be instrumental as we advance our portfolio of rare product candidates through late-stage clinical development and towards commercialisation.”. ... Most recently, Hughes-Wilson
-
Sobi appoints Norbert Oppitz SVP, speciality care
He joins the rare disease pharma firm from BSN Medical. Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established
-
Bo Jesper Hansen to step down as chairman of Sobi
Biovitrum and Swedish Orphan International in 2010. ... Hansen joined Swedish Orphan International AB in 1993 and served as its chief executive officer between 1998 and 2010.
-
Zealand adds two observers to board of directors
Nicklasson has held various executive VP positions at AstraZeneca and was president and CEO of BioVitrum and Swedish Orphan Biovitrum.
More from appointments
Approximately 2 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
